Benefits of laparoscopic prostate-sparing radical cystectomy.

abstract：:The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30 years since the advent of combination chemotherapy with cytarabine arabinoside and daunorubicin with remission rates around 70% but with long term survival still only around 40% in young adults. Doses of chemotherapy have been push...

journal_title：Expert review of anticancer therapy

authors： Kell J

更新日期：2016-01-01 00:00:00

abstract：:Ovarian cancer is the leading cause of gynecologic cancer-related death in Europe and the USA. The optimal treatment strategy for this malignancy includes accurate presurgical and surgical staging, optimal debulking surgery, and first-line therapy with platinum-based chemotherapy. Unfortunately, the majority of patien...

journal_title：Expert review of anticancer therapy

authors： Guarneri V,Barbieri E,Dieci MV,Piacentini F,Conte P

更新日期：2011-01-01 00:00:00

abstract：:The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and melanoma progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signaling can inhibit multiple cellular processes involved in melanoma progression and me...

journal_title：Expert review of anticancer therapy

authors： De Giorgi V,Grazzini M,Gandini S,Benemei S,Asbury CD,Marchionni N,Geppetti P

更新日期：2012-11-01 00:00:00

abstract：INTRODUCTION:Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents (azacitidine/decitabine), growth factor support, lenalidomide, and ...

journal_title：Expert review of anticancer therapy

authors： Feld J,Belasen A,Navada SC

更新日期：2020-06-01 00:00:00

abstract：:While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trial...

journal_title：Expert review of anticancer therapy

authors： Dellinger TH,Monk BJ

更新日期：2009-07-01 00:00:00

abstract：:Accelerated partial breast irradiation has been investigated in selected patients with early-stage breast cancer. Accelerated partial breast irradiation limits the radiation target to the volume of tissue immediately surrounding the lumpectomy cavity and reduces the overall treatment time from approximately 6 weeks to...

journal_title：Expert review of anticancer therapy

authors： Cuttino LW,Vicini FA

更新日期：2011-09-01 00:00:00

abstract：:For most sporadic cancers, genetic susceptibility results from the additive effect of multiple genetic variants, each of which contributes a modest risk individually. The study of genetic single nucleotide polymorphisms (SNPs) may help explain the differences in individual cancer susceptibility and may assist in ident...

journal_title：Expert review of anticancer therapy

authors： Meyer LA,Westin SN,Lu KH,Milam MR

更新日期：2008-07-01 00:00:00

abstract：:Malignant gliomas are the most prevalent type of primary brain tumor in adults. Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. The median survival of patients with glioblastoma multiforme, the most common grade of malignant glioma, is 10-12 months. Conventional ther...

journal_title：Expert review of anticancer therapy

authors： Sathornsumetee S,Rich JN

更新日期：2006-07-01 00:00:00

abstract：:Glioblastoma multiforme (GBM) is the most common primary brain malignancy. The current standard of therapy consists of surgical resection followed by concurrent chemoradiotherapy with temozolomide. Despite steady advances in all therapeutic modalities, clinical improvements have been slow and the prognosis remains poo...

journal_title：Expert review of anticancer therapy

authors： Wardak Z,Choe KS

更新日期：2013-11-01 00:00:00

abstract：:Renal neoplasms exhibit a wide spectrum of molecular characteristics that are closely associated with their diverse morphologic manifestations and clinical behaviors. A wealth of information has been garnered via methodology ranging from classical cytogenetics to FISH and gene expression profiling; however, the exact ...

journal_title：Expert review of anticancer therapy

authors： Cheng L,Williamson SR,Zhang S,Maclennan GT,Montironi R,Lopez-Beltran A

更新日期：2010-06-01 00:00:00

abstract：INTRODUCTION:Endometrial cancer is a common gynecologic malignancy in the United States, and the recurrence rate depends on the disease stage at diagnosis. Recurrence can affect several areas and follow different patterns. AREAS COVERED:The role of surgery at the time of recurrence is not clearly defined. In this revi...

journal_title：Expert review of anticancer therapy

authors： Zanfagnin V,Ferrero A,Biglia N,Aletti G,Gill SE,Makdisi PB,Multinu F,Mariani A

更新日期：2016-07-01 00:00:00

abstract：:The development of consensus classifications for renal epithelial neoplasia in 1996 and 1997 led to the recognition of renal adenoma, renal oncocytoma and metanephric adenoma/adenofibroma as benign tumors and conventional (clear cell) renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and collecting duct carci...

journal_title：Expert review of anticancer therapy

authors： Delahunt B,Velickovic M,Grebe SK

更新日期：2001-12-01 00:00:00

abstract：INTRODUCTION:Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immun...

journal_title：Expert review of anticancer therapy

authors： Kamath SD,Kalyan A,Benson AB 3rd

更新日期：2018-12-01 00:00:00

abstract：:The advent of granulocyte colony-stimulating factor, in particular filgrastim, in clinical use more than 10 years ago made a significant impact on the management of neutropenia and its complications. More recently, the application of pegylation technology has created a second-generation molecule, pegfilgrastim, with s...

journal_title：Expert review of anticancer therapy

authors： Ng R,Green MD

更新日期：2005-08-01 00:00:00

abstract：:Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the data in relation to the pharmacology and mode of action of capecitabine, followed by an in-depth review of the available c...

journal_title：Expert review of anticancer therapy

authors： Kelly C,Cassidy J

更新日期：2007-06-01 00:00:00

abstract：:In clinical practice, approximately 50% of new cases of breast cancer occur in women over the age of 65 years, although very few elderly women have been enrolled in the numerous randomized trials conducted so far. Notwithstanding less aggressive biologic features compared with younger patients, breast cancer impacts o...

journal_title：Expert review of anticancer therapy

authors： Basso U,Brunello A,Pogliani C,Monfardini S

更新日期：2004-04-01 00:00:00

abstract：:Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarker...

journal_title：Expert review of anticancer therapy

authors： Reed AB,Parekh DJ

更新日期：2010-01-01 00:00:00

abstract：:Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical results have revealed better properties, that is, larger efficacy and lower toxicity for these substances than for conventional anti-cancer treatments. Here, we review the development of several o...

journal_title：Expert review of anticancer therapy

authors： Alphandéry E,Grand-Dewyse P,Lefèvre R,Mandawala C,Durand-Dubief M

更新日期：2015-01-01 00:00:00

abstract：:Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever pos...

journal_title：Expert review of anticancer therapy

authors： Vijayamurugan N,Bakhshi S

更新日期：2014-02-01 00:00:00

abstract：INTRODUCTION:Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast c...

journal_title：Expert review of anticancer therapy

authors： Griguolo G,Dieci MV,Guarneri V,Conte P

更新日期：2018-06-01 00:00:00

abstract：:Despite its increasing incidence over the last 30 years, the mortality rate of papillary thyroid cancer (PTC) has decreased significantly. Nevertheless, a minority of patients still present with an aggressive form of PTC that can lead to death, even after a prolonged period of survival. Many classifications exist that...

journal_title：Expert review of anticancer therapy

authors： Miccoli P,Miccoli M,Antonelli A,Minuto MN

更新日期：2009-09-01 00:00:00

abstract：:Although testicular cancer is currently a rare disease, the incidence is rising. The most important risk factor remains cryptorchism and there is a variable association with testicular microlithiasis. Serum tumor markers remain important for diagnosis, and they have prognostic value and can be used to monitor therapy ...

journal_title：Expert review of anticancer therapy

authors： Balk C,Witjes JA

更新日期：2004-08-01 00:00:00

abstract：:One of the most prominent pathways explored in the area of targeted therapy is the PI3K/Akt/mTOR pathway, which plays a central role in cell survival and proliferation. Deregulation of this pathway has been implicated in the promotion of cancer cell growth and survival. Inhibition of several steps of this pathway has ...

journal_title：Expert review of anticancer therapy

authors： Georgakis GV,Younes A

更新日期：2006-01-01 00:00:00

abstract：INTRODUCTION:Tamoxifen, as an essential therapeutic tool in the treatment of estrogen receptor-positive breast cancer, has been available for the past three decades and is currently being utilized as a chemo-preventive agent for patients at high risk for breast carcinoma. However, the induction of chemo-resistance duri...

journal_title：Expert review of anticancer therapy

authors： Merikhian P,Ghadirian R,Farahmand L,Mansouri S,Majidzadeh-A K

更新日期：2017-07-01 00:00:00

abstract：:Recurrent non muscle invasive bladder cancer (NMIBC) represents a therapeutic challenge, especially in the case of Bacillus Calmette Guerin (BCG)-failures. Chemohyperthermia (CHT) has been tested as adjuvant therapy in selected categories of patients with promising results. The aim of this systematic review is to expl...

journal_title：Expert review of anticancer therapy

authors： Soria F,Allasia M,Oderda M,Gontero P

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Despite a variety of therapies for advanced metastatic colorectal cancer being available, the outcomes in this malignancy remain suboptimal. Immunotherapy has been slow to impact the management of this patient group. Checkpoint inhibitors, such as nivolumab, have had disappointing results when used broadly...

journal_title：Expert review of anticancer therapy

authors： Smith KM,Desai J

更新日期：2018-07-01 00:00:00

abstract：:Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase I...

journal_title：Expert review of anticancer therapy

authors： Surmont VF,van Meerbeeck JP

更新日期：2011-10-01 00:00:00

abstract：:Lung cancer is a global health issue. Compared with other common malignancies, the prognosis is poor as many patients present with advanced disease. The National Lung Screening Trial (NLST) aimed to identify and treat early lung cancers using annual low-dose computed tomography (CT) screening in a high-risk group. Whe...

journal_title：Expert review of anticancer therapy

authors： Duke SL,Eisen T

更新日期：2011-12-01 00:00:00

abstract：:The incidence of thyroid cancer is increasing by 4% per year. Thyroid cancer has become the eighth most common malignancy diagnosed in women. Papillary cancer accounts for 80% of all thyroid cancer. The management of papillary thyroid cancer is challenging, primarily because there have been no prospective randomized t...

journal_title：Expert review of anticancer therapy

authors： Rosenbaum MA,McHenry CR

更新日期：2009-03-01 00:00:00

abstract：:The incidence of renal cell cancer is increasing and surgery is the only curative treatment for patients presenting with localized disease at diagnosis. The treatment of metastatic renal cell cancer is palliative and, until recently, immunotherapy has been the standard treatment approach with response rates between 10...

journal_title：Expert review of anticancer therapy

authors： Gore ME,Harrison ML,Montes A

更新日期：2007-01-01 00:00:00